AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16211739
Drug: Granisetron 0.2
RxNorm normalized name: granisetron 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 0.2 mg
Trial: 16211739
Drug: Granisetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 0.3 mg
Trial: 16211739
Drug: Granisetron (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (all doses)
Trial: 12423702
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated estrogens
Trial: 12423702
Drug: Transdermal estradiol‐17‐beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol‐17‐beta with progestins
Trial: 10606212
Drug: Calcium HMB
RxNorm normalized name: calcium HMB/vitamin D3 0.5 gram-2.08 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium HMB supplementation (3 to 6 g x d(‐1))
Trial: 1747493
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg tid)
Trial: 1747493
Drug: Clebopride (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clebopride (0.5 mg tid)
Trial: 26565438
Drug: Hybrid Constraint
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid Constraint Induced Movement Therapy (hCIMT)
Trial: 26565438
Drug: Distributed individual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distributed individual occupational therapy (OT)
Trial: 23852397
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus weekly split-dose cisplatin (SWP)
Trial: 23852397
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus standard-dose cisplatin (SP)
Trial: 23065071
Drug: Low-dose tricyclic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tricyclic antidepressants
Trial: 17708846
Drug: Glutamine treatment
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine treatment group (0.4 g/kg per day for 7 days)
Trial: 12776266
Drug: Long daily
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long daily regimen (prednisolone 60 mg/m2 for 6 weeks, then 40 mg/m2 alternate-day for 6 weeks)
Trial: 12776266
Drug: Long alternate-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long alternate-day regimen (prednisolone 60 mg/m2 for 4 weeks, then 60 mg/m2 alternate-day for 4 weeks, tapering by 10 mg/m2 every 4 weeks)
Trial: 10367871
Drug: Oral contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contrast solution (OC)
Trial: 10367871
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral contrast solution (no OC)
Trial: 8566682
Drug: CBS 480
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS 480 mg daily during 6 weeks
Trial: 8566682
Drug: M 1
RxNorm normalized name: CRM 197
DrugBank: Corynebacterium diphtheriae CRM197 protein (DB16712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M 1 g daily during 6 weeks
Trial: 8566682
Drug: CBS 480
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS 480 mg daily plus M 750 mg daily during 4 weeks
Trial: 8566682
Drug: CBS 480
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS 480 mg daily plus Amoxycillin 1500 mg daily during 4 weeks
Trial: 8566682
Drug: M 750
RxNorm normalized name: aniracetam 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M 750 mg daily plus Amoxycillin 1500 mg daily during 4 weeks
Trial: 2166253
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg/die
Trial: 2166253
Drug: Quinapril 20
RxNorm normalized name: quinapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 20 mg/die
Trial: 2166253
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg/die
Trial: 2166253
Drug: Quinapril 40
RxNorm normalized name: quinapril 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 40 mg/die
Trial: 7428405
Drug: Sustained-release clonidine
RxNorm normalized name: clonidine Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release clonidine (250 or 500 micrograms/day)
Trial: 7428405
Drug: Standard tablet
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tablet clonidine (300 or 450 micrograms/day)
Trial: 7428405
Drug: Sustained-release clonidine
RxNorm normalized name: clonidine Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release clonidine
Trial: 30103252
Drug: Oral apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral apixaban (10 mg twice daily for the first 7 days, then 5 mg twice daily)
Trial: 30103252
Drug: Subcutaneous dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dalteparin (200 IU/kg for the first month, then 150 IU/kg once daily)
Trial: 22739038
Drug: 1% diquafosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% diquafosol ophthalmic solution
Trial: 22739038
Drug: 1% and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% and 3% diquafosol ophthalmic solutions
Trial: 15753792
Drug: Thyroglobulin (Tg)
RxNorm normalized name: thyroglobulin
DrugBank: Thyroglobulin (DB01584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroglobulin (Tg) measurement <2 ng/ml
Trial: 15753792
Drug: Ablation dose
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablation dose (AD)
Trial: 11965203
Drug: Thrombolysis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis with aspirin
Trial: 27535131
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) group-based enhancement to home visiting (HV/CBT)
Trial: 16776752
Drug: Intensive mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive mixture therapy (IMT) using insulin lispro mixture 50/50 before breakfast and lunch and insulin lispro mixture 25/75 before dinner
Trial: 16776752
Drug: Intensive mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive mixture therapy (IMT)
Trial: 11426092
Drug: Dihydroergotamine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine 0.25 mg intravenously
Trial: 9431382
Drug: Separate administration
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate administration of DTaP, hepatitis B vaccine, and PRP-T vaccine
Trial: 9431382
Drug: Combination DTaP-hepatitis
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination DTaP-hepatitis B vaccine-PRP-T
Trial: 9431382
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of CRM197-OS
Trial: 7032489
Drug: Injection
RxNorm normalized name: Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: 21125466
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion 80 mmol/day
Trial: 15053497
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment program including fines, community service, monetary restitution, written essays, anti-shoplifting videos, apology letters, and individual and/or family counseling
Trial: 15053497
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment program
Trial: 8882238
Drug: Midazolam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (5 mg.70 kg‐1 bolus at induction followed by 1 mg.70 kg‐1.h‐1 continuous infusion for 48 h)
Trial: 6613138
Drug: High-dose irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose irradiation of 40 to 66 Gy (59 cases)
Trial: 6613138
Drug: Simultaneous irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous irradiation and COMP chemotherapy (80 cases including 30 survivors)
Trial: 30813934
Drug: Intramuscular 17-alpha
RxNorm normalized name: 17-alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 17-alpha hydroxprogesterone caproate (17P)
Trial: 21822678
Drug: Habitual diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habitual diet plus additional food supplement (SUP, n=15)
Trial: 15339761
Drug: Duloxetine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 80 mg/d for 4 weeks, escalated to 120 mg/d for 4 weeks
Trial: 9138335
Drug: Citarabine (standard,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citarabine (standard, intermediate or high doses) combined with daunomicin or mitoxantrone
Trial: 2476604
Drug: Potassium supplements
RxNorm normalized name: POTASSIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium supplements (64 mmol daily)
Trial: 27330154
Drug: Intact hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact hydrocodone ER 45-mg tablet
Trial: 27330154
Drug: Finely crushed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finely crushed hydrocodone ER 45-mg tablet
Trial: 27330154
Drug: Hydrocodone IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone IR 45-mg powder
Trial: 24816760
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of tranexamic acid (TXA) 500 mg in 20 mL of normal saline solution, applied into the joint for 5 min at the end of surgery.
Trial: 24816760
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received an equivalent volume of normal saline solution, applied into the joint for 5 min at the end of surgery.
Trial: 19736249
Drug: Psychiatric examination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychiatric examination including diagnostics with Present State Examination and feedback regarding treatment and rehabilitation; 329 (78.3%) participated in the intervention.
Trial: 16893434
Drug: ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe 10 mg-simvastatin 20 mg
Trial: 16893434
Drug: placebo-simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo-simvastatin 20 mg
Trial: 15336577
Drug: Intravenous regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regular insulin
Trial: 10950401
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (amlodipine 5 mg and doxazosin 2 mg)
Trial: 10950401
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with doxazosin 4 mg
Trial: 10950401
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with amlodipine 10 mg
Trial: 9305715
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus amifostine (500 mg/m2 carboplatin + 2 doses of 910 mg/m2 amifostine)
Trial: 9305715
Drug: Carboplatin alone
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin alone (500 mg/m2)
Trial: 8422661
Drug: Selegiline 0
RxNorm normalized name: selegiline 0.5 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline 0 mg daily (placebo)
Trial: 3537783
Drug: Intravenous edrophonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous edrophonium (Tensilon)
Trial: 29582447
Drug: Sleep study-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep study-guided multidisciplinary therapy (SGMT) including overnight sleep study, continuous positive airway pressure, and behavioral therapy for OSA.
Trial: 29582447
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for acute coronary syndrome (ACS).
Trial: 22388001
Drug: Nebivolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (10 mg and 20 mg daily)
Trial: 20478471
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic mixture (ciprofloxacin, metronidazole, minocycline)
Trial: 20478471
Drug: Minocycline (component
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (component of the triple antibiotic paste)
Trial: 18387728
Drug: Dentin bonding
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentin bonding agent
Trial: 15939717
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy with 5-Fluorouracil (5-FU) and cisplatin
Trial: 7751410
Drug: Linopirdine (DuP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linopirdine (DuP 996) 0.5 to 55 mg in young subjects; 20 to 45 mg in elderly subjects
Trial: 2148280
Drug: Low-dose enoximone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose enoximone
Trial: 2148280
Drug: High-dose enoximone
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose enoximone
Trial: 359109
Drug: Butorphanol 1
RxNorm normalized name: butorphanol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 1 mg and 2 mg
Trial: 359109
Drug: Meperidine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 40 mg and 80 mg
Trial: 31222759
Drug: Metabolite-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolite-guided treatment approach
Trial: 26069973
Drug: Wet cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet cupping therapy (6 sessions within 2 weeks at two bladder meridian acupuncture points)
Trial: 23791771
Drug: Professionally applied
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professionally applied dentine bonding agent (DA)
Trial: 21680999
Drug: Remoxy 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxy 5 mg twice daily (10 mg total daily oxycodone dose) for opioid-naïve patients; equivalent dose for opioid-experienced patients based on previous opioid daily dose.
Trial: 14713399
Drug: Cyclooxygenase-2 selective
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclooxygenase-2 selective agents
Trial: 7516450
Drug: CODE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CODE plus G‐CSF (cyclophosphamide, Oncovin, doxorubicin, etoposide with granulocyte-colony stimulating factor)
Trial: 2887173
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg WAL 801 CL
Trial: 2887173
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg WAL 801 CL
Trial: 2887173
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg WAL 801 CL
Trial: 2887173
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg ketotifen
Trial: 27635789
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose CT (120 kVp, 100 mAs)
Trial: 24628076
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 25 mcg
Trial: 24431884
Drug: Insulin syringe
RxNorm normalized name: Insulin Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin syringe
Trial: 21353107
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg/d or Naproxen 250 mg BID for 8 weeks
Trial: 21353107
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg/d or Naproxen 250 mg BID for 6 months
Trial: 21353107
Drug: Mean postbaseline
RxNorm normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean postbaseline sUA concentration <6.0 mg/dL
Trial: 18275573
Drug: Progesterone suppository
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone suppository (400 mg) daily until delivery
Trial: 14969070
Drug: Early DMARD
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early DMARD group (hydroxychloroquine, intramuscular gold, oral methotrexate)
Trial: 14969070
Drug: iAU therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iAU therapy
Trial: 10382188
Drug: Liquid nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid nutritional supplement between meals and at bedtime
Trial: 8694698
Drug: pyruvate-based peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyruvate-based peritoneal dialysis solution (pH 5.2)
Trial: 8694698
Drug: lactate-based peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactate-based peritoneal dialysis solution (control)
Trial: 6341639
Drug: Rhesus diploid‐cell‐strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus diploid‐cell‐strain rabies vaccine (RDRV)
Trial: 6341639
Drug: Rhesus diploid‐cell‐strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus diploid‐cell‐strain rabies vaccine (RDRV) without prior rabies immune globulin
Trial: 27128218
Drug: AZD6280 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6280 10 mg
Trial: 27128218
Drug: AZD6280 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6280 40 mg
Trial: 21309709
Drug: Derris scandens
RxNorm normalized name: Senecio scandens flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derris scandens Benth extracts 800 mg/day
Trial: 11597664
Drug: Bosentan (62.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (62.5mg taken twice daily for 4 weeks then 125 mg twice daily)
Trial: 9408514
Drug: Gentamicin 7
RxNorm normalized name: gentamicin 70 mg/50 mL-0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 7 mg/kg i.v. once daily by itself
Trial: 9408514
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with piperacillin 4 g and tazobactam 0.5 g every six hours i.v.
Trial: 9408514
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with piperacillin 4 g and tazobactam 0.5 g every eight hours i.v.
Trial: 9408514
Drug: Gentamicin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin with piperacillin 8 g and tazobactam 1 g by continuous i.v. infusion over 24 hours
Trial: 7961338
Drug: Fluoxetine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine at a dose of 0.6 mg/kg/day
Trial: 3328992
Drug: Anxiety Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiety Management (self-help treatment including procedures for managing somatic and cognitive symptoms, avoidance, and low self-confidence)
Trial: 28057390
Drug: Lornoxicam 16mg
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 16mg administered 60 minutes before surgery
Trial: 28057390
Drug: Lornoxicam 16mg
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 16mg administered 60 minutes after surgery
Trial: 28057390
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 60 minutes before surgery
Trial: 28057390
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 60 minutes after surgery
Trial: 23143621
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg thalidomide once/day
Trial: 23143621
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g sulfasalazine, twice/day
Trial: 23143621
Drug: NSAIDs for
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs for maintenance treatment